Iovance Biotherapeutics (IOVA) Set to Announce Quarterly Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.01. Iovance Biotherapeutics had a negative net margin of 1,343.27% and a negative return on equity of 65.04%. The business had revenue of $31.11 million during the quarter, compared to the consensus estimate of $24.59 million. During the same quarter in the previous year, the firm posted ($0.47) EPS. The firm’s revenue was up 12969.7% on a year-over-year basis. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iovance Biotherapeutics Stock Performance

Shares of IOVA stock traded up $0.16 during mid-day trading on Tuesday, reaching $11.60. 3,237,418 shares of the company’s stock traded hands, compared to its average volume of 7,096,503. Iovance Biotherapeutics has a 12 month low of $3.76 and a 12 month high of $18.33. The firm has a 50 day moving average price of $10.17 and a two-hundred day moving average price of $9.80. The firm has a market capitalization of $3.25 billion, a PE ratio of -6.72 and a beta of 0.60.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IOVA. Piper Sandler downgraded shares of Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $19.00 to $10.00 in a research report on Monday, July 29th. UBS Group began coverage on shares of Iovance Biotherapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $17.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a research report on Monday, August 12th. Finally, StockNews.com raised shares of Iovance Biotherapeutics to a “sell” rating in a research report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.33.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.